Barbara S. Giesser, MD Professor of Clinical Neurology Medical Director, Multiple Sclerosis Achievement Center Clinical Director, Multiple Sclerosis Program David Geffen School of Medicine at UCLA Los Angeles, CA Lawrence M. Samkoff, MD Associate Professor of Neurology Attending Neurologist Neuroimmunology Unit Department of Neurology University of Rochester Medical Center Rochester, NY
Kirstin Nygren, MSN, NP, MSCN Nurse Practitioner, Multiple Sclerosis Clinic Department of Neurology David Geffen School of Medicine at UCLA Los Angeles, CA
AMA PRA Category 1 Credit TM
ANCC: 0.75 contact hours (0.25 contact hours are in the area of pharmacology) Medium
This activity, the second in a 3-part series focused on shared decision making and patient-centered care in MS, will examine the differences in MS disease-modifying therapies (DMT) and provide guidance for working together with patients to select appropriate first-line treatment.
. Target Audience
This activity is designed for neurologists, mental health specialists, physician assistants (PAs), and nurse practitioners (NPs) as well as nurses and other professionals who care for patients and families affected by MS.
Upon completion of this educational activity, the participant should be able to:
Outline key opportunities for use of motivational interviewing and a shared decision-making approach to improve the selection of first-line MS disease-modifying therapy.
Discuss differences in MS disease-modifying therapies, including differences in efficacy and safety, dosing frequency, and administration options.
Barbara S. Giesser, MD, has disclosed the following relationship:
Grant/Research support from Biogen.
Lawrence M. Samkoff, MD, has disclosed no relevant financial relationships.
Kirstin Nygren, MSN, NP, MSCN, has disclosed no relevant financial relationships.
Laurie Scudder, DNP, NP, has served as Nurse Planner and Reviewer for this activity. She has disclosed no relevant financial relationships.
CMSC and NPA staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Barbara J. Martin, MD, medical writer, has disclosed no relevant financial relationships.
Kathleen Hines, MCM Education VP, Editorial Affairs, has disclosed no relevant financial relationships.
Terry Ann Glauser, MD, MPH, MCM Education VP, Medical Affairs, has disclosed no relevant financial relationships.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling. Credit Statements
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Consortium of Multiple Sclerosis Centers (CMSC), Nurse Practitioner Alternatives (NPA), and MCM Education. CMSC is accredited by the ACCME to provide continuing medical education for physicians.
CMSC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s) TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Alternatives is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NPA designates this enduring activity for 0.75 continuing nursing education credits (0.25 contact hours are in the area of pharmacology).
Commercial Support Statements
Supported by educational grants from AbbVie, Inc. and Genzyme, a Sanofi Company.
Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
Please turn off all pop-up blockers to allow access to the educational activity.
Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 45 minutes to complete.
After you have finished reviewing the activity, click on the "Post-test" button.
Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen.
©2016, MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the Consortium of Multiple Sclerosis Centers, NP Alternatives, AbbVie, Inc., or Genzyme. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.